Alphaderm cream (Urea and hydrocortisone)

Alphaderm is a combination of urea and hydrocortisone. It is available for topical application for the treatment of:

Alphaderm dose in Adults

Alphaderm dose in the treatment of Steroid-responsive dermatoses:

Topical:
- It is applied as thin film and rub in well 2-4 times/day.
- Therapy should be stopped when control is achieved
- if no improvement is seen, reassessment of diagnosis might be necessary.

Alphaderm Dose in Childrens

Refer to adult dosing.

Pregnancy Risk Factor C

Teratogenic effects have been seen in animals administered potent topical corticosteroids.
It is not recommended to use topical products for prolonged periods of time or in large quantities in pregnant women.

Use of hydrocortisone and uraea during lactation:

Alphaderm Dose in Renal Disease:

No dose adjustment is required.

Alphaderm Dose in Liver Disease:

No dose adjustmen is required.

Side Effects of Alphaderm

Side effects are mentioned for the individual medicine.
Topical side effects may include skin irritation and photosensitivity.
The risk of infection is increased. When applied to a greater skin area, the risk of systemic absorption may result in adrenal suppression.

Warnings and precaution

Suppression of the adrenals:
- Systemic absorption of topical corticosteroids might cause hypercortisolism or suppression of the hypothalamic-pituitary-adrenal (HPA) axis, mainly in younger children or in patients receiving high doses for prolonged periods.
- Suppression of the HPA axis can cause adrenal crisis.
Immunosuppression:
- Long-term use could lead to fungal and bacterial superinfections
- If the dermatological infection persists, despite proper antimicrobial treatment, you should stop immediately
Sensitization:
- Use of topical products can cause local irritation (redness, redness) and should be discontinued if this is the case.
Systemic effects
- Percutaneous absorption of topical corticosteroids may be possible.
- The absorption of topical corticosteroids may lead to Cushing's syndrome, hyperglycemia or glycosuria.
- Application of occlusive dressings to denuded skin, or to large areas of the skin can increase absorption.

Urea and hydrocortisone: Drug Interaction

Risk Factor C (Monitor therapy)
Calcipotriene	Hydrocortisone (Topical) may diminish the therapeutic effect of Calcipotriene. Management: Monitor for reduced calcipotriene efficacy if combined with hydrocortisone valerate. Consider separating the administration of these agents by 10 to 12 hours to minimize the risk of this potential interaction.
Corticorelin	Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.
Deferasirox	Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.
Ritodrine	Corticosteroids may enhance the adverse/toxic effect of Ritodrine.
Risk Factor D (Consider therapy modification)
Hyaluronidase	Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.
Risk Factor X (Avoid combination)
Aldesleukin:	Corticosteroids may diminish the antineoplastic effect of Aldesleukin.